Osveh Pharmaceutical Company (DOSVE) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DOSVE
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/09/30 | To 1401/09/30 | To 1400/09/30 |
|---|---|---|---|---|---|---|
| Operating revenue | 24,737,998 | 6,427,331 | 5,558,031 | 7,099,327 | 5,512,064 | 4,120,103 |
| Cost of operating revenue | -11,690,415 | -3,997,804 | -5,082,792 | -4,847,692 | -2,822,786 | -1,712,255 |
| Gross profit (loss) | 13,047,583 | 2,429,527 | 475,239 | 2,251,635 | 2,689,278 | 2,407,848 |
| Selling, general and administrative expenses | -942,956 | -470,474 | -418,099 | -478,528 | -224,929 | -216,764 |
| Other income | 1,714 | 4,052 | 4,980 | 6,045 | 8,643 | 3,732 |
| Other expenses | -92,538 | -92,307 | -119,604 | -29,576 | -64,448 | -7,665 |
| Operating profit (loss) | 12,013,803 | 1,870,798 | -57,484 | 1,749,576 | 2,408,544 | 2,187,151 |
| Finance costs | -378,072 | -428,636 | -750,696 | -533,822 | -146,347 | -239,647 |
| Other non-operating income and expenses | 497,717 | 241,243 | 429,904 | 422,414 | 740,238 | 182,459 |
| Profit (loss) from continuing operations before tax | 12,133,448 | 1,683,405 | -378,276 | 1,638,168 | 3,002,435 | 2,129,963 |
| Current year tax | -2,237,262 | -272,200 | -76,450 | -253,602 | -502,540 | -434,422 |
| Net profit (loss) from continuing operations | 9,896,186 | 1,411,205 | -454,726 | 1,384,566 | 2,499,895 | 1,695,541 |
| Net profit (loss) | 9,896,186 | 1,411,205 | -454,726 | 1,384,566 | 2,499,895 | 1,695,541 |
| Basic earnings (loss) per share | 13,195 rials | 1,881 rials | -606 rials | 1,846 rials | 3,333 rials | 2,261 rials |
| Net earnings (loss) per share, rials | 13,195 rials | 1,882 rials | -606 rials | 1,847 rials | 3,334 rials | 2,261 rials |
| Capital | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 | 750,000 |
Reporting periods
92 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.